BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)
- First Posted Date
- 2010-10-11
- Last Posted Date
- 2016-06-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 33
- Registration Number
- NCT01218477
- Locations
- 🇺🇸
University Of California Medical Center, San Francisco, California, United States
🇺🇸Ut M.D. Anderson Cancer Center, Houston, Texas, United States
🇬🇧Local Institution, Glasgow, United Kingdom
Effect of Diltiazem on Pharmacokinetics of BMS-914392
- First Posted Date
- 2010-09-30
- Last Posted Date
- 2011-02-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT01211808
- Locations
- 🇺🇸
Pra International, Lenexa, Kansas, United States
Effect of BMS-914392 on Pharmacokinetics of Metoprolol
- First Posted Date
- 2010-09-30
- Last Posted Date
- 2011-02-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 18
- Registration Number
- NCT01211821
- Locations
- 🇺🇸
Pra International, Lenexa, Kansas, United States
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
- Conditions
- Hepatitis B Virus
- Interventions
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 197
- Registration Number
- NCT01204762
- Locations
- 🇺🇸
Sc Clinical Research, Inc., Garden Grove, California, United States
🇺🇸Mercy Medical Center, Baltimore, Maryland, United States
🇺🇸Office Of Sing Chan Md, Flushing, New York, United States
Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 13
- Registration Number
- NCT01195727
- Locations
- 🇺🇸
The Toledo Children'S Hospital, Toledo, Ohio, United States
🇺🇸Penn State Hershey Children'S Hospital, Hershey, Pennsylvania, United States
🇺🇸Children'S Hospital Of Orange County, Orange, California, United States
Ph IIA Study (SOC +/- NS5B)
- Conditions
- Hepatitis C Virus
- Interventions
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 39
- Registration Number
- NCT01193361
- Locations
- 🇺🇸
Options Health Research, Llc, Tulsa, Oklahoma, United States
🇺🇸Advanced Clinical Research Institute, Anaheim, California, United States
🇺🇸Loyola University Medical Center, Maywood, Illinois, United States
Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 173
- Registration Number
- NCT01188278
Methotrexate - Inadequate Response Device Sub-Study
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- Device: Abatacept combination product (ACP)
- First Posted Date
- 2010-07-30
- Last Posted Date
- 2012-01-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 62
- Registration Number
- NCT01173120
Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment
- Conditions
- Hepatitis C Virus
- Interventions
- First Posted Date
- 2010-07-28
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 512
- Registration Number
- NCT01170962
- Locations
- 🇺🇸
Scripps Clinic, La Jolla, California, United States
🇺🇸Alabama Liver & Digestive Specialists (Alds), Montgomery, Alabama, United States
🇺🇸Liver Associates Of Texas, Houston, Texas, United States
Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 11
- Registration Number
- NCT01167244
- Locations
- 🇯🇵
Local Institution, Koto-Ku, Tokyo, Japan